Video
Importance of understanding patterns in prostate genomic testing
Author(s):
Video Player is loading.
In this video, Scarlett Gomez, MD, PhD, discusses the significance of the private public collaboration between the National Cancer Institute’s Surveillance Epidemiology, and End Results program and the Oncotype DX Genomic Prostate Score assay in investing patterns in prostate genomic testing.Gomez is a professor in the department of epidemiology and biostatistics at the University of California, San Francisco.
Related Videos
Sima Porten, MD, discusses the need to educate on the firefighter-bladder cancer link
Matthew Cooperberg, MD, on racial disparities in prostate, bladder cancer outcomes
Matthew Cooperberg, MD, reacts to 2025 ACS prostate cancer data
Paul Sieber, MD, on the future of genetic testing in prostate cancer
Daniel Kwon, MD, discusses study’s impact on veteran access to germline testing for prostate cancer
Tim Richardson, MD, on genetic testing in the era of targeted therapies
Discussing germline testing for prostate cancer with veterans
Kara Cossis, PA-C, MPH, on the role of APPs in genetic testing
Tim A. Richardson, MD, outlines key settings for genetic testing in prostate cancer
Germline testing study’s implications for veteran access to prostate cancer treatments
Related Content
May 23rd 2022
